Pharmaceuticals Kenya

Kenya Oncology Biosimilars Market Analysis, 2024–2034

Kenya Oncology Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Kenya · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $6.4 Mn Estimated value
Estimate 2025 $7.4 Mn 0.1% of the global market
Projected 2034 $27.6 Mn 274.4% Adds $20.2 Mn over 9 forecast years
CAGR 2025–2034 15.8% Faster than 74% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Kenya is 0.06% of the global market.
  • In Africa, the largest is South Africa at $79.0 Mn.
  • Fastest growing: Egypt at 16.8% a year.
  • Kenya ranks 3rd of 3 by size in Africa.

Market size projection

Kenya

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$20.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Oncology Biosimilars Market market size by year, Kenya
YearMarket sizeChange that yearSince 2025
2024 (estimate) $6.4 Mn — —
2025 (base) $7.4 Mn +$1.0 Mn —
2026 (forecast) $8.5 Mn +$1.2 Mn +15.8%
2027 (forecast) $9.9 Mn +$1.3 Mn +34.1%
2028 (forecast) $11.5 Mn +$1.6 Mn +55.3%
2029 (forecast) $13.3 Mn +$1.8 Mn +79.8%
2030 (forecast) $15.4 Mn +$2.1 Mn +108.2%
2031 (forecast) $17.8 Mn +$2.4 Mn +141.1%
2032 (forecast) $20.6 Mn +$2.8 Mn +179.2%
2033 (forecast) $23.8 Mn +$3.3 Mn +223.3%
2034 (forecast) $27.6 Mn +$3.8 Mn +274.4%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $11.90 Bn
  2. North America $6.50 Bn
  3. US $4.41 Bn
  4. Europe $2.39 Bn
  5. APAC $2.20 Bn
  6. China $927.5 Mn
  7. Canada $887.7 Mn
  8. Japan $636.5 Mn
  9. Latin America $578.1 Mn
  10. Germany $452.7 Mn
  11. Middle East $471.5 Mn
  12. France $371.6 Mn
  13. Brazil $336.0 Mn
  14. Italy $302.5 Mn
  15. UK $282.2 Mn
  16. Ecuador $236.9 Mn
  17. Spain $202.5 Mn
  18. India $212.2 Mn
  19. Saudi Arabia $205.4 Mn
  20. Mexico $160.2 Mn
  21. Africa $157.7 Mn
  22. Australia $148.3 Mn
  23. New Zealand $138.8 Mn
  24. Russia $110.4 Mn
  25. South Africa $79.0 Mn
  26. UAE $51.8 Mn
  27. Egypt $35.2 Mn
  28. Philippines $22.8 Mn
  29. Hong Kong $22.1 Mn
  30. Malaysia $18.0 Mn
  31. Thailand $16.5 Mn
  32. Singapore $12.8 Mn
  33. Kenya (this report) $7.4 Mn

The Kenya Oncology Biosimilars Market Analysis Executive Summary

Oncology biosimilars are lower-cost versions of cancer biologic drugs such as trastuzumab and bevacizumab.

Key segments of the oncology Biosimilars market include molecule (Trastuzumab, Bevacizumab and Rituximab) and cancer (Breast, Colorectal and Lymphoma).

Kenya Oncology Biosimilars Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the oncology Biosimilars market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the oncology Biosimilars market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the oncology Biosimilars market, especially in low- and middle-income countries.

Competitive Landscape for Oncology Biosimilars Market in Kenya

The oncology Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Oncology Biosimilars Market in Kenya

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oncology Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Kenya.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Oncology Biosimilars right now, from free public sources.

Latest research 23 papers since 2021 (worldwide)

  1. Adoption of Bevacizumab Biosimilars in Medicare Part B: Socioeconomic and Geographic Variation, 2019-2023. JCO oncology practice, 2026
  2. Pricing for Oncology Biosimilars. JAMA, 2026
  3. Pricing for Oncology Biosimilars-Reply. JAMA, 2026
  4. Hospital Adoption and Pricing for Oncology Biosimilars. JAMA, 2026
  5. Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients. Pharmacy (Basel, Switzerland), 2025
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Oncology Biosimilars in context

Kenya compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.29 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 3.0% of people (2025). World: 10.4% of people (2025). 10th highest of the 17 countries we cover in Africa.[3]

Questions, answered with public data

How much research is published on Oncology Biosimilars?
PubMed lists 23 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Oncology Biosimilars in Kenya? Our analysts can size it for your plan. Talk to us See the public data Early deaths from long-term diseases (WHO) for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Kenya

See all
Same topic, other categories

Related on oncology and biologics and biosimilars

See the topic